Understanding the involvement of innate immunity and the Nrf2-NLRP3 axis on mitochondrial health in Parkinson's disease
- PMID: 36963313
- DOI: 10.1016/j.arr.2023.101915
Understanding the involvement of innate immunity and the Nrf2-NLRP3 axis on mitochondrial health in Parkinson's disease
Abstract
Parkinson's disease (PD), a multifactorial movement disorder, is interlinked with numerous molecular pathways, including neuroinflammation, which is a critical factor in the development and progression of PD. Microglia play a central role in driving neuroinflammation through activation and overexpression of the M1 phenotype, which has a significant impact on mitochondria. Multiple regulators converge together, and among these, the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasomes have been implicated in transmitting inflammatory and deleterious components to the mitochondria. Nuclear factor erythroid 2-related factor 2 (Nrf2) regulates the NLRP3 inflammasome and acts as the saviour of the mitochondria. Together, the NLRP3-Nrf2 axis functions in regulating mitochondrial function in the case of PD. It regulates fundamental processes such as oxidative stress, mitochondrial respiratory function, and mitochondrial dynamics. In this review, we discuss the contributions that a variety of miRNAs make to the regulation of the NLRP3 inflammasome and Nrf2, which can be used to target this important axis and contribute to the preservation of mitochondrial integrity. This axis may prove to be a crucial target for extending the lives of Parkinson's patients by deferring neuroinflammatory damage to mitochondria.
Keywords: Innate immunity; Mitochondria; NLRP3; Neuroinflammation; Nrf2; Parkinson’s disease.
Copyright © 2023 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
Similar articles
-
Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease.Front Immunol. 2021 Oct 8;12:719807. doi: 10.3389/fimmu.2021.719807. eCollection 2021. Front Immunol. 2021. PMID: 34691027 Free PMC article. Review.
-
NF-κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective.J Cell Mol Med. 2023 Jul;27(13):1775-1789. doi: 10.1111/jcmm.17784. Epub 2023 May 21. J Cell Mol Med. 2023. PMID: 37210624 Free PMC article. Review.
-
NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson's Disease.Neurosci Bull. 2023 May;39(5):832-844. doi: 10.1007/s12264-023-01023-y. Epub 2023 Feb 9. Neurosci Bull. 2023. PMID: 36757612 Free PMC article. Review.
-
Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson's disease: mechanisms and therapeutic implications.J Neurol. 2023 Mar;270(3):1346-1360. doi: 10.1007/s00415-022-11491-3. Epub 2022 Dec 3. J Neurol. 2023. PMID: 36460875 Free PMC article. Review.
-
Parkinson's disease: connecting mitochondria to inflammasomes.Trends Immunol. 2022 Nov;43(11):877-885. doi: 10.1016/j.it.2022.09.010. Epub 2022 Oct 11. Trends Immunol. 2022. PMID: 36229358 Review.
Cited by
-
Oxidative Stress: Pathological Driver in Chronic Neurodegenerative Diseases.Antioxidants (Basel). 2025 Jun 9;14(6):696. doi: 10.3390/antiox14060696. Antioxidants (Basel). 2025. PMID: 40563328 Free PMC article. Review.
-
Emerging role of Nrf2 in Parkinson's disease therapy: a critical reassessment.Metab Brain Dis. 2024 Dec 19;40(1):70. doi: 10.1007/s11011-024-01452-2. Metab Brain Dis. 2024. PMID: 39699763 Review.
-
Repurposing of epalrestat for neuroprotection in parkinson's disease via activation of the KEAP1/Nrf2 pathway.J Neuroinflammation. 2025 Apr 29;22(1):125. doi: 10.1186/s12974-025-03455-x. J Neuroinflammation. 2025. PMID: 40301912 Free PMC article.
-
Unraveling the role of Nrf2 in dopaminergic neurons: a review of oxidative stress and mitochondrial dysfunction in Parkinson's disease.Metab Brain Dis. 2025 Feb 11;40(2):123. doi: 10.1007/s11011-025-01552-7. Metab Brain Dis. 2025. PMID: 39932604 Review.
-
Targeting the NLRP3 inflammasome as a novel therapeutic target for osteoarthritis.Inflammopharmacology. 2025 Feb;33(2):461-484. doi: 10.1007/s10787-024-01629-2. Epub 2025 Jan 13. Inflammopharmacology. 2025. PMID: 39806051 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical